Translate Bio Announces Pricing of Public Offering of Common Stock
September 17 2019 - 9:06PM
Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA
(mRNA) therapeutics company developing a new class of potentially
transformative medicines to treat diseases caused by protein or
gene dysfunction, today announced the pricing of its underwritten
public offering of 9,000,000 shares of its common stock at a public
offering price of $10.00 per share, for aggregate gross proceeds of
$90 million, before deducting underwriting discounts and
commissions and offering expenses payable by Translate Bio. In
addition, Translate Bio has granted the underwriters a 30-day
option to purchase up to 1,350,000 additional shares of common
stock at the public offering price, less the underwriting discounts
and commissions. All of the shares are being sold by Translate Bio.
The offering is expected to close on September 20, 2019, subject to
the satisfaction of customary closing conditions.
Citigroup, Jefferies and SVB Leerink are acting as joint
book-running managers for the offering. The shares are being
offered by Translate Bio pursuant to an effective shelf
registration statement that was filed with the Securities and
Exchange Commission (SEC) on July 3, 2019 and declared effective by
the SEC on July 19, 2019.
This offering is being made only by means of a prospectus and
prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement relating to and
describing the terms of the offering has been filed with the SEC
and may be obtained for free by visiting the SEC’s website at
www.sec.gov. The final prospectus supplemented relating to the
offering will be filed with the SEC. When available, copies of the
final prospectus supplement and the accompanying prospectus may
also be obtained by contacting: Citigroup Global Markets Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, telephone: 1-800-831-9146; Jefferies LLC, Attention:
Equity Syndicate Prospectus Departments, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, by phone at (877) 821-7388, or by email
at Prospectus_Department@Jefferies.com; or SVB Leerink LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6132, or by
email at syndicate@svbleerink.com.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of, these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Translate BioTranslate Bio is a
clinical-stage mRNA therapeutics company developing a new class of
potentially transformative medicines to treat diseases caused by
protein or gene dysfunction. Translate Bio’s mRNA therapeutic
platform (MRT platform) is designed to develop product candidates
that deliver mRNA carrying instructions to produce intracellular,
transmembrane and secreted proteins for therapeutic benefit.
Translate Bio is primarily focused on applying its MRT platform to
pulmonary diseases caused by insufficient protein production or
where production of proteins can modify disease. Translate Bio also
believes that its technology is applicable to a broad range of
diseases, including diseases that affect the liver, eye and the
central nervous system. Additionally, the MRT platform may be
applied to various classes of treatments, such as therapeutic
antibodies or vaccines in areas such as infectious disease and
oncology. Translate Bio’s lead program is being developed as a
treatment for cystic fibrosis (CF) and is in an ongoing Phase 1/2
clinical trial.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include, but are not limited to, those
regarding the expected closing of the offering and anticipated
proceeds from the offering. The words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “would” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual
events or results to differ materially from current expectations
and beliefs, including but not limited to: market and other
financing conditions; Translate Bio’s ability to advance the
development of its platform and programs under the timelines it
projects; demonstrate the requisite safety and efficacy of its
product candidates and replicate in later-stage clinical trials any
positive findings from preclinical studies; the content and timing
of decisions made by the U.S. Food and Drug Administration, other
regulatory authorities and investigational review boards at
clinical trial sites, including as it relates to ongoing and
planned clinical trials; Translate Bio’s ability to obtain,
maintain and enforce necessary patent and other intellectual
property protection; the availability of significant cash required
to fund operations; competitive factors; general economic and
market conditions and other important risk factors set forth under
the caption “Risk Factors” in the preliminary prospectus relating
to the offering , Translate Bio’s Quarterly Report on Form 10-Q for
the quarterly period ended June 30, 2019 and in any other
subsequent filings made with the SEC by Translate Bio. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Translate Bio specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Contacts for Translate Bio
Investors Teri
Dahlman tdahlman@translate.bio 857-242-7792
|
MediaMaura
Gavaghanmgavaghan@translate.bio 857-242-7789 |
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Oct 2023 to Oct 2024